Effect of a combined treatment with erythropoietin and melatonin on renal ischemia reperfusion injury in male rats

Clinical and Experimental Nephrology

Volumn 18, Issue 6, 2014, Pages 855-864

  Ahmadiasl, Nasser ^a   Banaei, Shokofeh ^b   Alihemati, Alireza ^b   Baradaran, Behzad ^b   Azimian, Ehsan ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PAYAME NOOR UNIVERSITY   (Iran)

Author keywords

Antioxidants; Erythropoietin; Ischemia reperfusion injury; Kidney; Melatonin

Indexed keywords

ERYTHROPOIETIN; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MELATONIN; SUPEROXIDE DISMUTASE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BASEMENT MEMBRANE; BLOOD LEVEL; BLOOD SAMPLING; BOWMAN CAPSULE; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; KIDNEY INJURY; KIDNEY ISCHEMIA; MALE; MILD RENAL IMPAIRMENT; NONHUMAN; RAT; RENAL PROTECTION; REPERFUSION; REPERFUSION INJURY; UREA BLOOD LEVEL; ACUTE KIDNEY INJURY; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG COMBINATION; KIDNEY; METABOLISM; PATHOLOGY; VASCULARIZATION; WISTAR RAT;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; GLUTATHIONE PEROXIDASE; KIDNEY; MALE; MALONDIALDEHYDE; MELATONIN; MODELS, ANIMAL; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; SUPEROXIDE DISMUTASE;

EID: 84919875848     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-0937-6     Document Type: Article

References (64)

1. Grace PA. Ischaemia-reperfusion injury. Br J Surg. 1994;81:637–47.
2. Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, Ward PA. Ischemia-reperfusion injury. J Surg Res. 2002;105:248–58.
3. Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RW, Najarian JS, Matas AJ. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: the multivariate analysis. Transplantation. 1995;59:962–8.
4. Masztalerz M, Wlodarczyk Z, Czuczejko J, Slupski M, Kedziora J. Superoxide anion as a marker of ischemia-reperfusion injury of the transplanted kidney. Transpl Proc. 2006;38:46–8.
5. Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med. 2000;109:655–78.
6. Das DK, Maulik N. Antioxidant effectiveness in ischemia reperfusion tissue injury. Methods Enzymol. 1994;233:601–10.
7. Ikeda K, Negishi H, Yamori Y. Antioxidant nutrients and hypoxia/ischemia brain injury in rodents. Toxicology. 2003;189:55–61.
8. Rakotovao A, Berthonneche C, Guiraud A, de Lorgeril M, Salen P, de Leiris J, Boucher F. Ethanol, wine, and experimental cardioprotection in ischemia/reperfusion: role of the prooxidant/antioxidant balance. Antioxid Redox Signal. 2004;6:431–8.
9. Glantzounis GK, Salacinski HJ, Yang W, Davidson BR, Seifalian AM. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review. Liver Transpl. 2005;11:1031–47.
10. Kacmaz A, Polat A, User Y, Tilki M, Ozkan S, Sener G. Octreotide improves reperfusion-induced oxidative injury in acute abdominal hypertension in rats. J Gastrointest Surg. 2004;8:113–9.
11. Singh D, Chander V, Chopra K. Protective effect of catechin on ischemia-reperfusion-induced renal injury in rats. Pharmocal Rep. 2005;57:70–6.
12. Benjamin B, Ebert L, Bunn HF. Regulation of erythropoietin gene. Blood. 1999;94:1864–77.
13. Siren AL, Ehrenreich H. Erythropoietin: a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci. 2001;251:179–84.
14. Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res. 2004;1000:19–31.
15. Westenfelder C, Biddle DL, Baranowski RL. Human, rat and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55:808–20.
16. Calo LA, Bertipaglia L, Pagnin E. Antioxidants, carnitine and erythropoietin. G Ital Nefrol. 2006;34:47–50.
17. Aluclu MU, Acar A, Guzel A, Bahceci S, Yaldiz M. Evaluation of erythropoietin effects on cerebral ischemia in rats. Neuro Endocrinol Lett. 2007;28:170–4.
18. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006;48:2161–7.
19. Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, Yaqoob M, Thiemermann C, Mota-Filipe H. Recombinant human erythropoietin protects the liver from hepatic ischemia reperfusion injury in the rat. Transpl Int. 2006;19:919–26.
20. Wu H, Ren B, Zhu J, Dong G, Xu B, Wang C, Zheng X, Jing H. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg. 2006;29:902–7.
21. Plotnikov EY, Chupyrkina AA, Jankauskas SS, Pevzner IB, Silachev DN, Skulachev VP, Zorov DB. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta. 2011;1812:77–86.
22. Poeggeler B, Saarela S, Reiter RJ, Tan DX, Chen LD, Manchester LC, Barlow-Warden LR. Melatonin: a highly potent endogenous radical scavenger and electron donor new aspects of the oxidation chemistry of this indole accessed in vitro. Ann NY Acad Sci. 1994;17:419–29.
23. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci. 2000;7:444–58.
24. Reiter RJ, Tan DX, Pilar Terron M, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings egarding their production and their radical scavenging actions. Acta Biochim Pol. 2007;54:1–9.
25. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J. 1993;1:57–60.
26. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189–200.
27. Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, Reiter RJ. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine(AMK), in macrophages. J Neuroimmunol. 2005;165:139–49.
28. Reiter RJ, Tan DX, Maldonado MD. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005;39:215–6.
29. Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1–9.
30. Maldonado MD, Murillo-Cabezas F, Terron MP, Flores LJ, Tan DX, Manchester LC, Reiter RJ. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res. 2007;42:1–11.
31. Reiter RJ, Guerrero JM, Garcia JJ, Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging: relation to melatonin. Ann NY Acad Sci. 1998;854:410–24.
32. Kurcer Z, Oguz E, Ozbilge H, Baba F, Aksoy N, Celik H, Cakir H, Gezen MR. Melatonin protects from ischemia/reperfusion-induced renal injury in rats: this effect is not mediated by proinflammatory cytokines. J Pineal Res. 2007;43(2):172–8.
33. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Ann Intensive Care. 2011;1(1):3.
34. Yagi K. Assay for blood plasma or serum. Methods Enzymol. 1984;105:328–31.
35. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–69.
36. Ey Sšzmen, Sšzmen B, Delen Y, Onat T. Catalase/superoxide dismutase (SOD) and catalase/paraoxanase (PON) ratio may implicate poor glycemic control. Arch Med Res. 2001;32:283–7.
37. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application for monitoring the antioxidant status in premature neonates. Clin Sci. 1993;84:407–12.
38. Kiris I, Kapan S, Kilbas A, Yilmaz N, Altuntaş I, Karahan N, Okutan H. The protective effect of erythropoietin on renal injury induced by abdominal aortic-ischemia-reperfusion in rats. J Surg Res. 2008;149:206–13.
39. Carden DL, Granger DN. Pathophysiology of ischemia reperfusion injury. J Pathol. 2000;190:255–66.
40. Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, Brodsky S, Goligorsky MS. Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol. 2001;281:F948–57.
41. Sekhon CS, Sekhon BK, Singh I, Orak JK, Singh AK. Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. J Nephrol. 2003;16:63–74.
42. Kevin LG, Novalija E, Stowe DF. Reactive oxygen species as mediators of cardiac injury and protection: the relevance to anesthesia practice. Anesth Analg. 2005;101:1275–87.
43. McCord JM. The evaluation of free radicals and oxidative stress. Am J Med. 2000;108:652–9.
44. Hagiwara S, Koga H, Iwasaka H, Kudo K, Hasegawa A, Kusaka J, Yokoi I, Noguchi T. ETS-GS, a new antioxidant, ameliorates renal ischemia-reperfusion injury in a rodent model. J Surg Res. 2011;171:226–33.
45. Schoenberg MH, Beger HG. Reperfusion injury after intestinal ischemia. Crit Med Care. 1993;21:1376–86.
46. Mun KC, Lee HG, Lee TH, Kim YH, Kwak CS, Kim SP, Chang EJ, Park SB, Kim HC. Effect of modified polyhemoglobin on the ischemia/reperfusion injury in kidney. Transpl Proc. 2003;35:99–100.
47. Kiris I, Okutan H, Savas C, Yönden Z, Delibaş N. Deneysel aortic iskemi-reperfuzyon modelinde renal hasara gadolinium klorurun etkisi.Turkish. J Vasc Surg. 2005;14:13–8.
48. Chen CF, Hsueh CW, Tang TS, Wang D, Shen CY, Pei JS. Reperfusion liver injury induced superoxide dismutase and catalase expressions and the protective effects of N-acetyl cysteine. Transpl Proc. 2007;39:858–60.
49. Gulmen S, Kiris I, Narin C, Ceylan BG, Mermi B, Sutcu R, Meteoglu I. Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res. 2009;157:e7–13.
50. Evans P, Halliwell B. Micronutrients: oxidant/antioxidant status. Br J Nutr. 2001;85:S67–74.
51. Dimitrijevic ZM, Cvetkovic TP, Djordjevic VM, Pavlovic DD, Stefanovic NZ, Stojanovic IR, Paunovic GJ, Velickovic-Radovanovic RM. How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients. Int J Med Sci. 2012;9(9):808–15.
52. Ates E, Yalcin AU, Yılmaz S, Koken T, Tokyol C. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg. 2005;75:1100–5.
53. Reiter RJ, Oh C-S, Fujimori O. Melatonin: its intracellular and genomic actions. Trends Endocrinol Metab. 1996;7:22–7.
54. Paller MS. Pathophysiologic mechanisms of acute renal failure. In: Goldstein RS, editor. Mechanisms of injury in renal disease and toxicity. Michigan: Ann Arbor CRC Press; 1994. p. 3–13.
55. Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transpl. 2006;21:330–6.
56. Quiroz Y, Ferrebuz A, Romero F, Vaziri ND, Rodriguez-Iturbe B. Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol. 2008;294(2):F336–44.
57. Song Y, Chan CW, Brown GM, Pang SF, Silverman M. Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule. FASEB J. 1997;11(1):93–100.
58. Singh I, Gulati S, Orak JK, Singh AK. Expression of antioxidant enzymes in rat kidney during ischemia-reperfusion injury. Mol Cell Biochem. 1993;125:97–104.
59. Davies SJ, Reichardt-Pascal SY, Vaughan D, Russell GI. Differential effect of ischaemia-reperfusion injury on anti-oxidant enzyme activity in the rat kidney. Exp Nephrol. 1995;3:348–54.
60. Conti M, Eschwege P, Ahmed M, Paradis V, Droupy S, Loric S, Bedossa P, Charpentier B, Legrand A, Benoit G. Antioxidant enzymatic activities and renal warm ischemia: correlation with the duration of ischemia. Transpl Proc. 2000;32:2740–1.
61. Li Z, Nickkholgh A, Yi X, Bruns H, Gross ML, Hoffmann K, Mohr E, Zorn M, Büchler MW, Schemmer P. Melatonin protects kidney grafts from ischemia/reperfusion injury through inhibition of NF-kB and apoptosis after experimental kidney transplantation. J Pineal Res. 2009;46:365–72.
62. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects he kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115–24.
63. Vesey DA, Cheung C, Pat B, Endre Z, Gobé G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348–55.
64. Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y, Yegen BC. The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J Pineal Res. 2002;32:120–6.